SRS 2025: Society of Robotic Surgery Event in Strasbourg

<h2 dir="ltr">What&rsquo;s Next for MedTech?&nbsp;</h2>
<h2 dir="ltr">-Dr. Dylan Attard, CEO, MedTech World</h2>
<p dir="ltr">The healthcare industry is entering a period of profound transformation. Once marked by incremental progress, today&rsquo;s medical technology landscape is evolving at an unprecedented pace. This momentum is not driven by a single innovation, but rather by the convergence of emerging technologies, increasing patient expectations, and a shifting global investment environment. The question is no longer what lies ahead for MedTech, but how quickly we can adapt to the changes already underway.</p>
<h3 dir="ltr">Robotics Expanding Beyond the Operating Room</h3>
<p dir="ltr">One of the most striking developments is the expanding role of robotics in healthcare. Traditionally associated with high-precision surgical interventions, robotics is now influencing nearly every aspect of care delivery. According to MarketsandMarkets, the global medical robots market&mdash;valued at $16.0 billion in 2024&mdash;is projected to reach $33.8 billion by 2029, reflecting a compound annual growth rate of over 16%. This growth is not confined to the operating room. Robotic systems are being deployed for rehabilitation, delivering personalized therapy and speeding up patient recovery, while automation technologies are streamlining hospital logistics, pharmacy operations, and infection control. Far from replacing clinicians, these tools are designed to extend their capabilities, reduce strain, and improve clinical workflows.</p>
<p><strong>&nbsp;</strong></p>
<h3 dir="ltr">AI and Connectivity: Driving Intelligent Care</h3>
<p dir="ltr">Artificial intelligence is rapidly becoming an integral part of healthcare&rsquo;s digital backbone. Initially applied to diagnostics, AI is now enabling more personalized treatment planning, facilitating earlier detection of disease progression, and accelerating the development of new therapies. With a market forecast to grow from $26.69 billion in 2024 to over $613 billion by 2034, AI's integration into medical practice is expected to deepen across both clinical and operational domains. Notably, AI is also playing a critical role in enhancing robot-assisted procedures, further reinforcing its presence within the MedTech ecosystem.</p>
<p dir="ltr">Connectivity is another area seeing exponential growth. The rise of the Internet of Medical Things (IoMT) is enabling real-time patient monitoring, remote diagnostics, and continuous data exchange between patients and providers. As a result, interventions are becoming more timely and proactive, contributing to better outcomes. The global IoMT market is expected to exceed one trillion dollars by 2034, up from $242.80 billion in 2024. This growth reflects the mounting demand for integrated, efficient systems that extend care beyond traditional clinical settings.</p>
<p><strong>&nbsp;</strong></p>
<h3 dir="ltr">Personal Health, Precision, and Immersive Technologies</h3>
<p dir="ltr">Wearable health technologies are gaining traction by giving individuals greater control over their health. From basic fitness trackers to advanced biosensors, these tools are fostering a more engaged, data-driven approach to personal wellbeing. Virtual and augmented reality technologies are also reshaping clinical education, surgical simulation, and even pain management strategies, bringing immersive solutions into both hospitals and training centers.</p>
<p dir="ltr">Another major frontier lies in precision medicine. Advances in genomics and pharmacogenomics are enabling treatments that align more closely with individual biological profiles, offering improved outcomes and reducing the risk of adverse effects. This shift from a one-size-fits-all approach to highly personalized care is redefining what effective medicine looks like in the 21st century.</p>
<p dir="ltr">Sustainability, meanwhile, is becoming a growing priority across the industry. As awareness of healthcare&rsquo;s environmental impact grows, many companies are embracing eco-conscious manufacturing processes and circular economy principles. Responsible innovation will not only shape the future of MedTech but also ensure its alignment with broader global goals.</p>
<p><strong>&nbsp;</strong></p>
<h3 dir="ltr">Investment Confidence and Market Consolidation</h3>
<p dir="ltr">Despite global economic uncertainties, MedTech continues to attract investor interest. In 2024, venture capital funding surpassed the previous year&rsquo;s total, reaching $19.1 billion across nearly 700 deals. Investor confidence appears resilient, though more selective, with capital increasingly concentrated in high-impact areas such as digital health, robotics, and AI-driven platforms.</p>
<p dir="ltr">Mergers and acquisitions are also on the rise. The industry recorded 305 M&amp;A transactions in 2024, the second-highest count in a decade. Larger players are actively seeking to expand product portfolios, access new capabilities, and increase operational efficiency. Johnson &amp; Johnson&rsquo;s $13.1 billion acquisition of Shockwave Medical is one of several headline deals highlighting renewed interest in consolidation. The uptick in acquisitions of venture-backed companies further suggests that a healthy exit environment is returning for startups.</p>
<p dir="ltr">Alongside investment activity, regulatory engagement is also evolving. Authorities are taking a more collaborative approach with innovators, helping to shape ethical frameworks for the adoption of new technologies while streamlining approval processes. This closer alignment is expected to facilitate faster yet safer go-to-market strategies for emerging solutions.</p>
<p><strong>&nbsp;</strong></p>
<h3 dir="ltr">Looking Ahead: Collaboration Will Define Progress</h3>
<p dir="ltr">What emerges from this landscape is a MedTech industry defined not solely by invention, but by meaningful integration. The real opportunity lies in how these technologies converge to improve patient care, empower clinicians, and make healthcare more efficient, accessible, and sustainable.</p>
<p dir="ltr">At <a href="https://med-tech.world/medtech-malta-2025/?utm_source=web&amp;utm_medium=post&amp;utm_campaign=opinionated-piece" target="_blank" rel="noopener">MedTech World</a>, we are committed to advancing this future. From November 12 to 14, 2025, we will bring together leaders, startups, investors, and global stakeholders at <a href="https://med-tech.world/medtech-malta-2025/?utm_source=web&amp;utm_medium=post&amp;utm_campaign=opinionated-piece" target="_blank" rel="noopener">MedTech Malta 2025</a>. Held in the historic city of Valletta, this three-day gathering will offer attendees the chance to engage with transformative ideas, forge new partnerships, and explore the innovations actively shaping the next era of healthcare.</p>
<p dir="ltr">In a time of accelerating change, understanding the direction of MedTech has never been more essential. We invite you to be part of that conversation.</p>
<p dir="ltr"><img src="db886051-acfa-4270-9b2a-8f9f76749e13" alt=""></p>
<p>&nbsp;</p>

What’s Next for MedTech?

<div data-scaffold-immersive-reader-content="">
<div>
<div class="reader-article-content reader-article-content--content-blocks" dir="ltr">
<div class="reader-content-blocks-container" tabindex="0" data-artdeco-is-focused="true">
<p id="ember48" class="ember-view reader-text-block__paragraph">I recently had the chance to chat with <a id="ember49" class="ember-view" href="https://www.linkedin.com/in/davidnconstantine/">David N Constantine</a> , an experienced medtech entrepreneur and the Co-founder and CEO of <a class="app-aware-link " href="https://www.linkedin.com/company/juniper-biomedical/" data-test-app-aware-link="">Juniper Biomedical</a>.</p>
<p id="ember50" class="ember-view reader-text-block__paragraph">At Juniper, they&rsquo;re working on innovative neuromodulation technology to tackle pelvic health issues. Their approach uses neuromodulation and focuses on super precise micro-implants that target specific nerves, offering new treatment possibilities for conditions that currently lack good options.</p>
<p id="ember51" class="ember-view reader-text-block__paragraph">In our chat, David talked about his path, the challenges of bringing groundbreaking technology to life, and his vision for where neurotech is headed.</p>
<p id="ember52" class="ember-view reader-text-block__paragraph">Let's get into it....</p>
<div class="reader-image-block reader-image-block--resize">
<figure class="reader-image-block__figure">
<div class="ivm-image-view-model   ">
<div class="ivm-view-attr__img-wrapper
        
        "><img id="ember53" class="ivm-view-attr__img--centered  reader-image-block__img evi-image lazy-image ember-view" src="https://media.licdn.com/dms/image/v2/D4E12AQGKVlCPmSAMUQ/article-inline_image-shrink_1500_2232/article-inline_image-shrink_1500_2232/0/1726486569188?e=1733356800&amp;v=beta&amp;t=TusiZVRsgzR4a6sQoq20hLiZBuRTOSpKjfK183STezg" alt="" loading="lazy"></div>
</div>
</figure>
</div>
<blockquote id="ember54" class="ember-view reader-text-block__blockquote"><strong>Tell me about your background and the journey that brought you to where you are today?</strong></blockquote>
<p id="ember55" class="ember-view reader-text-block__paragraph"><em>&ldquo;I began my career in medical technology as a biomedical engineer, working with multinational companies like Medtronic and Smith &amp; Nephew across different clinical domains. I later joined a well-funded startup that gave me a comprehensive view of how a company operates. Two things became clear to me: first, if I wanted to work on paradigm-changing solutions with a significant clinical impact, I needed to do so in a smaller or startup company. Large companies tend to focus on incremental changes - small adjustments that don&rsquo;t really push the boundaries of innovation. </em></p>
<p id="ember56" class="ember-view reader-text-block__paragraph"><em>If you want to pursue something with the potential for a major impact, it usually happens in an entrepreneurial setting. Second, smaller companies allow you to have a more direct influence on the overall direction of the company. In large organizations, it's challenging to "move the needle" because of their size - it's like steering a big ship. These realizations led me to focus on entrepreneurial ventures. Since then, I&rsquo;ve launched a few companies, mostly in healthcare, including ventures in both medical technology and digital health. I find working in medical technology rewarding because it&rsquo;s a concrete pursuit. There&rsquo;s no room for vague ideas; you&rsquo;re targeting specific clinical problems with cutting-edge technologies, aiming to make a profound impact on patients.&rdquo; </em></p>
<p id="ember57" class="ember-view reader-text-block__paragraph"></p>
<blockquote id="ember58" class="ember-view reader-text-block__blockquote"><strong>What is it about neurotech that drew you to this sector?</strong></blockquote>
<p id="ember59" class="ember-view reader-text-block__paragraph"><em>&ldquo;Neurotech and more specifically, neuromodulation, is one of the main frontiers in medical technology today. The nervous system is a primary control system in the body, and there&rsquo;s still a lot we don&rsquo;t fully understand, both in the central and peripheral nervous systems. This creates tremendous opportunities to build on early innovations from companies like Medtronic. These companies initially worked on cardiac rhythm management and later expanded their technologies to different parts of the body, setting a foundation for further advancements. </em></p>
<p id="ember60" class="ember-view reader-text-block__paragraph"><em>For a while, the field plateaued from a commercial perspective, but we&rsquo;re now seeing a significant resurgence in neuromodulation innovation. I believe the next 20 years or so will bring groundbreaking research and applications that will fundamentally change how we provide care to patients across a wide variety of medical conditions.&rdquo; </em></p>
<p id="ember61" class="ember-view reader-text-block__paragraph"></p>
<div class="reader-image-block reader-image-block--resize">
<figure class="reader-image-block__figure">
<div class="ivm-image-view-model   ">
<div class="ivm-view-attr__img-wrapper
        
        "><img id="ember62" class="ivm-view-attr__img--centered  reader-image-block__img evi-image lazy-image ember-view" src="https://media.licdn.com/dms/image/v2/D4E12AQGxnFkkKiL88g/article-inline_image-shrink_1500_2232/article-inline_image-shrink_1500_2232/0/1726486422285?e=1733356800&amp;v=beta&amp;t=tKez_z2C2nfUsohSajNX2xeNggt624h1fYZl73om_84" alt="" loading="lazy"></div>
</div>
</figure>
</div>
<p id="ember63" class="ember-view reader-text-block__paragraph"></p>
<blockquote id="ember64" class="ember-view reader-text-block__blockquote"><strong>Tell me about Juniper Biomedical. What product are you developing, and what problem does it solve?</strong></blockquote>
<p id="ember65" class="ember-view reader-text-block__paragraph"><em>&ldquo;We&rsquo;re developing innovative solutions for pelvic health conditions, an area that has been marginalized when it comes to innovation. Much of the focus in medical technology has been on cardiovascular, neurology, cancer, and orthopedic areas, which makes sense given the scale of those problems. However, this has left gaps in other areas, especially pelvic health for both men and women, but particularly for women. That's where we decided to focus our innovative efforts. </em></p>
<p id="ember66" class="ember-view reader-text-block__paragraph"><em>Our technology revolves around a unique neuromodulation microimplant designed to deliver very precise therapy to specific distal nerve targets. Most neuromodulation in the peripheral nervous system focuses on stimulating large nerve trunks with high power, often affecting surrounding tissues unintentionally. </em></p>
<p id="ember67" class="ember-view reader-text-block__paragraph"><em>In contrast, our approach targets very small, specific distal nerves and employs novel implantation methods. This precision allows us to explore new therapeutic applications for conditions with significant unmet needs. It opens up possibilities for creating new, more effective treatments where none currently exist. That potential for making a real difference drives our team&rsquo;s commitment to this project.&rdquo; </em></p>
<p id="ember68" class="ember-view reader-text-block__paragraph"></p>
<blockquote id="ember69" class="ember-view reader-text-block__blockquote"><strong>Where are you in the development process, and what are you currently focusing on?</strong></blockquote>
<p id="ember70" class="ember-view reader-text-block__paragraph"><em>&ldquo;We&rsquo;re currently conducting a clinical feasibility study. We&rsquo;ve done extensive preclinical work, much of it in-house, to deeply understand the anatomy, physiology, and how our technology interacts within those contexts. Our goal isn&rsquo;t just to gather the minimum data needed for regulatory approval but to come into the clinic with a well-characterized solution supported by robust data. </em></p>
<p id="ember71" class="ember-view reader-text-block__paragraph"><em>We&rsquo;ve built hundreds of working prototypes and have refined our innovation to a clinical design that&rsquo;s quite advanced. As a PMA (premarket approval) product and an active implantable device, we have the opportunity to build a lot of clinical evidence before we reach the market, and that's beneficial for everyone. We want to ensure that when we present our solution, it's backed by substantial evidence of safety and efficacy.&rdquo; </em></p>
<p id="ember72" class="ember-view reader-text-block__paragraph"></p>
<div class="reader-image-block reader-image-block--resize">
<figure class="reader-image-block__figure">
<div class="ivm-image-view-model   ">
<div class="ivm-view-attr__img-wrapper
        
        "><img id="ember73" class="ivm-view-attr__img--centered  reader-image-block__img evi-image lazy-image ember-view" src="https://media.licdn.com/dms/image/v2/D4E12AQHPt3dHhtk_UQ/article-inline_image-shrink_1500_2232/article-inline_image-shrink_1500_2232/0/1726486443990?e=1733356800&amp;v=beta&amp;t=-ycPpbNPh5qc2ZIgndGHpT3jccg6OI2XO5oRllubEqM" alt="" loading="lazy"></div>
</div>
</figure>
</div>
<p id="ember74" class="ember-view reader-text-block__paragraph"></p>
<blockquote id="ember75" class="ember-view reader-text-block__blockquote"><strong>What has been your approach to investment, and how much have you raised so far?</strong></blockquote>
<p id="ember76" class="ember-view reader-text-block__paragraph"><em>&ldquo;We closed an oversubscribed seed round in April with a $2 million target, preceded by several SAFE notes. A key aspect of our strategy has been to keep operations lean. Our team has done an exceptional job of using capital efficiently to conduct over 25 preclinical studies with hundreds of specimens and cadaver studies, all on a tight budget. This efficiency is a testament to the expertise of our team, where everyone has 20 to 30 years of experience in both large multinationals and startups. This experience has allowed us to stay lean, especially in an environment where seed and A-round investment is not at its peak.&rdquo; </em></p>
<p id="ember77" class="ember-view reader-text-block__paragraph"></p>
<blockquote id="ember78" class="ember-view reader-text-block__blockquote"><strong>I saw you won the SPARC Neuromod Prize from the NIH Common Fund. Can you tell us more about that?</strong></blockquote>
<p id="ember79" class="ember-view reader-text-block__paragraph"><em>&ldquo;Yes, it's a fantastic program. The NIH's SPARC initiative includes the Neuromod Prize, which is designed to foster and accelerate neuromodulation innovation for commercial use. They were looking for modalities that could affect multiple targets and manage off-target effects. Our technology aligns well with this, as it's designed to be precise and multi-targeted. The program has been very supportive, not just financially, but also by providing access to NIH expertise and relationships. The leadership and connections we've gained through this have been exceptional.&rdquo; </em></p>
<p id="ember80" class="ember-view reader-text-block__paragraph"></p>
<div class="reader-image-block reader-image-block--resize">
<figure class="reader-image-block__figure">
<div class="ivm-image-view-model   ">
<div class="ivm-view-attr__img-wrapper
        
        "><img id="ember81" class="ivm-view-attr__img--centered  reader-image-block__img evi-image lazy-image ember-view" src="https://media.licdn.com/dms/image/v2/D4E12AQHe-_GPP3HoIQ/article-inline_image-shrink_1500_2232/article-inline_image-shrink_1500_2232/0/1726486467890?e=1733356800&amp;v=beta&amp;t=b4El1k-ysRpYfPobF1PtDOWH1rMR_OhuwgpKgBNPjR8" alt="" loading="lazy"></div>
</div>
</figure>
</div>
<p id="ember82" class="ember-view reader-text-block__paragraph"></p>
<blockquote id="ember83" class="ember-view reader-text-block__blockquote"><strong>What has been the biggest challenge you've faced, and how did you overcome it?</strong></blockquote>
<p id="ember84" class="ember-view reader-text-block__paragraph"><em>&ldquo;That&rsquo;s a great question. For any entrepreneur, the biggest challenge is often the need for persistence and resilience. It&rsquo;s not about one specific hurdle; it&rsquo;s about managing a continuous flow of challenges in product development, clinical trials, operations, and fundraising. Our team excels at balancing adaptability with consistency. We don&rsquo;t jump off course based on every piece of advice, but when we see consistent evidence prompting a significant change, we act on it. </em></p>
<p id="ember85" class="ember-view reader-text-block__paragraph"><em>For example, our first device was wirelessly powered, which made it extremely small - about the size of a freckle. We later switched to a battery-powered device, which, while still very small (half the size of a US dime), was a significant technical shift. This decision came after conversations with patients, doctors, and investors, who indicated that a device requiring daily activation was an unattractive compliance challenge. So, we made the change promptly but carefully. It was a well-informed decision that we&rsquo;re proud of, and it demonstrates our ability to adapt when necessary.&rdquo; </em></p>
<p id="ember86" class="ember-view reader-text-block__paragraph"></p>
<blockquote id="ember87" class="ember-view reader-text-block__blockquote"><strong>Where do you see the biggest opportunities in neuro over the coming years?</strong></blockquote>
<p id="ember88" class="ember-view reader-text-block__paragraph"><em>&ldquo;There are many opportunities, especially in uncharted areas. While central nervous system interfaces get a lot of attention, there&rsquo;s also significant potential in the peripheral landscape. For innovators, one key opportunity lies in maintaining focus. Neuromodulation technologies can often be applied as platforms - used on different nerves to treat various conditions. However, this can lead to diverse applications that create systemic effects and side effects. </em></p>
<p id="ember89" class="ember-view reader-text-block__paragraph"><em>By focusing on a specific clinical domain, like pelvic health, we can apply a platform approach while maintaining focus. This allows us to concentrate on similar devices, clinical procedures, and commercial call points, while still cultivating a platform that can address multiple therapeutic needs. I believe this focused approach can be applied to other clinical disciplines or organ systems where neuromodulation or combined therapies could offer substantial benefits.&rdquo; </em></p>
<p id="ember90" class="ember-view reader-text-block__paragraph"></p>
<div class="reader-image-block reader-image-block--resize">
<figure class="reader-image-block__figure">
<div class="ivm-image-view-model   ">
<div class="ivm-view-attr__img-wrapper
        
        "><img id="ember91" class="ivm-view-attr__img--centered  reader-image-block__img evi-image lazy-image ember-view" src="https://media.licdn.com/dms/image/v2/D4E12AQHWPshlldrzQA/article-inline_image-shrink_1500_2232/article-inline_image-shrink_1500_2232/0/1726486491200?e=1733356800&amp;v=beta&amp;t=Oz-xC46KAJdbnIrWOc7evvDNHoYXAO2laCzP0YMFO0s" alt="" loading="lazy"></div>
</div>
</figure>
</div>
<p id="ember92" class="ember-view reader-text-block__paragraph"></p>
<blockquote id="ember93" class="ember-view reader-text-block__blockquote"><strong>What advice would you give to a first-time founder or someone starting their journey?</strong></blockquote>
<p id="ember94" class="ember-view reader-text-block__paragraph"><strong><em>"</em></strong><em>Resilience and persistence are key because this path is tough. Beyond that, the most important thing is to surround yourself with exceptional people - whether they are part of your core team, advisors, or investors. Be very selective about who you work with. The right people can make or break your experience. I&rsquo;ve learned this the hard way through multiple ventures, sometimes being the wrong fit myself or having the wrong fit in a teammate. It really comes down to a clear understanding of what&rsquo;s best for your venture and authentic communication around the table. Don&rsquo;t just jump at the first opportunity; it&rsquo;s worth waiting for the right people to come along, even if it takes time.&rdquo; </em></p>
<p id="ember95" class="ember-view reader-text-block__paragraph"></p>
<hr class="reader-divider-block__horizontal-rule">
<p id="ember96" class="ember-view reader-text-block__paragraph"></p>
<p id="ember97" class="ember-view reader-text-block__paragraph">I enjoyed the chat with David and it was interesting to hear how Juniper are utilising neuromodulation for pelvic health conditions. While they&rsquo;re still in the development phase, their work has the potential to make a significant difference in patient care.</p>
<p id="ember98" class="ember-view reader-text-block__paragraph">If you&rsquo;re keen on learning more about advancements in neurotech and staying updated, feel free to like, comment, or share 😀. Stay tuned for more to come</p>
</div>
</div>
</div>
</div>
<div class="mh4 mv6 flex-row align-items-center display-flex clear-both">&nbsp;</div>

How Juniper Biomedical are using Neuromodulation for pelvic health conditions

<p>A Search Firm Placing MedTech Pioneers in Transformative Roles to help us live longer healthier lives.</p>

About us

We are

<span>Changemakers</span>

<span>Impactful</span>

<p>Cruxx is a search firm that supports the most innovative healthcare companies on the planet. With a global focus and a team of deep sector experts, we are building the search firm for the modern day.</p>

<p class="h2">Our vision is a future of life-saving innovation. We help <span class="text--primary">accelerate medical technology</span> to a point that fringes on science fiction. We <span class="text--primary">advocate</span> for a new age of surgery to turn today&rsquo;s MedTech ideas into reality.</p>

<p>Meet the team</p>

Inspire and excite. Avoid fluff. Be clear, direct and transparent. Strip things to the base layer to build intentional, authentic relationships with partners.

We are relentless in our pursuit.

<span>Relentless</span>

<span>Purposeful</span>

We are purposeful.

<p>We're always on the hunt for talented people who thrive on building committed connections. We are curious, energetic, driven, open-minded, innovative, and lovers of learning, so if that sounds like you, you know just what to do.</p>

Careers

<h2>Be the changemaker</h2><p>&nbsp;</p><p>We're always on the hunt for talented people who thrive on building committed connections. We are curious, energetic, driven, open-minded, innovative, and lovers of learning, so if that sounds like you, you know just what to do.&nbsp;</p><p><a class="outlineBtn mt-3" href="/submit-your-cv/">Send your CV</a></p>

<p>Perks</p>

<p></p>

Contact CruxX

EXPLORE OUR INSIGHTS OR THE SURGIBOTS PODCAST

You have a thirst to learn about the latest medical innovation 

<p>Explore our Vacancies</p>

YOU WANT A MISSION, NOT A JOB.

You want to find a place to grow

YOU HAVE A PROBLEM TO SOLVE

You want to Hire the best people for your MedTech Mission 

<span class="text--white">MedTech Search at the</span> <span class="text--primary">Cutting Edge</span>

<p>You're Probably Here for 1 of 3 reasons</p>

<p>We place MedTech pioneers in leading companies to solve the world&rsquo;s biggest health problems.</p>

<p>Companies who are addressing the world’s biggest health <br>challenges through innovation.</p>

<h2 class="text--primary">Cruxx are the experts in building <br>and scaling MedTech companies.</h2>

<p>Our recruitment solutions</p>

<span>Cruxx are the experts in building and scaling MedTech companies.</span>

<span>Companies who are addressing the world’s biggest health challenges through innovation.</span>

<p>Stay up to date with the latest Cruxx news</p>

Sign up for industry content

<p><small>We specialise in matching pioneering talent with leading companies in the MedTech sector to address the world’s most pressing health challenges. Cruxx operates globally with a commitment to innovation, placing the aspirations and needs of our clients and candidates at the heart of our approach. We don’t just fill roles; we forge connections, facilitate breakthroughs, and fuel progress in medical technology and healthcare.</small></p>

Testimonials

<p>At Cruxx we are at the cutting edge of MedTech search. Working with innovators, to hire the talent who are bringing medical innovation to the world.</p>

We're Hiring

<p>At Cruxx, we understand the vast potential and intricate nuances of the MedTech sector. We have our fingers on the pulse of the latest advancements and opportunities worldwide. We pride ourselves on offering a personalised experience. Every person we work with is unique, and we tailor our approach to match their distinct aspirations and needs.</p><p>The world of medical technology is not just about devices and data; it's about real-world</p>

<p>impact on health outcomes. When you partner with Cruxx, you're aligning with a team that's deeply committed to addressing the world's most pressing health challenges.</p><p>At Cruxx, we believe in the power of meaningful connections. We're not just filling roles; we're building bridges between pioneering talent and leading companies. Choose Cruxx, and be part of a journey that redefines the future of healthcare.</p>

<p><small>Take a look at what our clients say...</small></p>

Don’t take our word for it

<p>Case Studies</p>